3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
1128
Carcinoma, Non-Small-Cell Lung
718
Neoplasms
545
Prostatic Neoplasms
502
Colorectal Neoplasms
438
Multiple Myeloma
336
Lung Neoplasms
309
Neoplasm Metastasis
288
Leukemia, Myeloid, Acute
263
Stomach Neoplasms
248
Carcinoma, Hepatocellular
245
Ovarian Neoplasms
225
Rectal Neoplasms
211
Colonic Neoplasms
204
Lymphoma, Follicular
200
Lymphoma
199
Leukemia
190
Uterine Cervical Neoplasms
181
Head and Neck Neoplasms
174
Pancreatic Neoplasms
171
Lymphoma, Non-Hodgkin
167
Leukemia, Lymphocytic, Chronic, B-Cell
166
Lymphoma, Large B-Cell, Diffuse
163
Recurrence
161
Melanoma
158
Precursor Cell Lymphoblastic Leukemia-Lymphoma
154
Squamous Cell Carcinoma of Head and Neck
147
Pain
141
Urinary Bladder Neoplasms
139
Brain Neoplasms
133
Interventions
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Interventional
×
Biochemically Recurrent Prostate Cancer
×
Clear all
NCT05794906
2026-05-19
ARASTEP
Bayer
Phase 3
Active not recruiting
985 enrolled